Last reviewed · How we verify

DTaP-IPV//PRP~T combined vaccine

Sanofi · Phase 3 active Biologic

DTaP-IPV//PRP~T combined vaccine is a Inactivated pentavalent vaccine Biologic drug developed by Sanofi. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children. Also known as: PENTAXIM™.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

At a glance

Generic nameDTaP-IPV//PRP~T combined vaccine
Also known asPENTAXIM™
SponsorSanofi
Drug classInactivated pentavalent vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

DTaP-IPV//PRP~T is a pentavalent inactivated vaccine combining five separate immunizations into one injection. It contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, inactivated poliovirus types 1/2/3, and conjugated Haemophilus influenzae type b capsular polysaccharide. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, conferring protection against these five serious bacterial and viral pathogens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-IPV//PRP~T combined vaccine

What is DTaP-IPV//PRP~T combined vaccine?

DTaP-IPV//PRP~T combined vaccine is a Inactivated pentavalent vaccine drug developed by Sanofi, indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

How does DTaP-IPV//PRP~T combined vaccine work?

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

What is DTaP-IPV//PRP~T combined vaccine used for?

DTaP-IPV//PRP~T combined vaccine is indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

Who makes DTaP-IPV//PRP~T combined vaccine?

DTaP-IPV//PRP~T combined vaccine is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

Is DTaP-IPV//PRP~T combined vaccine also known as anything else?

DTaP-IPV//PRP~T combined vaccine is also known as PENTAXIM™.

What drug class is DTaP-IPV//PRP~T combined vaccine in?

DTaP-IPV//PRP~T combined vaccine belongs to the Inactivated pentavalent vaccine class. See all Inactivated pentavalent vaccine drugs at /class/inactivated-pentavalent-vaccine.

What development phase is DTaP-IPV//PRP~T combined vaccine in?

DTaP-IPV//PRP~T combined vaccine is in Phase 3.

What are the side effects of DTaP-IPV//PRP~T combined vaccine?

Common side effects of DTaP-IPV//PRP~T combined vaccine include Injection site pain, erythema, or swelling, Fever, Irritability or fussiness, Drowsiness, Loss of appetite, Vomiting.

Related